US PATENT SUBCLASS 424 / 177.1
.~ Reduced antigenicity, reduced ability to bind complement, or reduced numbers of activated complement components (e.g., free from aggregated, denatured, fragmented, or polymerized immunoglobulins; free from proteolytic enzymes, etc.)

Current as of: June, 1999
Click HD for Main Headings
Click for All Classes

Internet Version by PATENTEC © 1999      Terms of Use


424 /   HD   DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS

130.1  DF  IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL {18}
177.1.~ Reduced antigenicity, reduced ability to bind complement, or reduced numbers of activated complement components (e.g., free from aggregated, denatured, fragmented, or polymerized immunoglobulins; free from proteolytic enzymes, etc.)

DEFINITION

Classification: 424/177.1

Reduced antigenicity, reduced ability to bind complement, or reduced numbers of activated complement components (e.g., free from aggregated, denatured, fragmented, or polymerized immunoglobulins; free from proteolytic enzymes, etc.):

(under subclass 130.1) Subject matter involving an

immunoglobulin preparation from which aggregated, denatured, fragmented, or polymerized immunoglobulins have been removed or prevented from forming; or from which plasma proteins, such as proteolytic enzymes, that contaminate an immunoglobulin preparation have been removed; or that has been treated to reduce the number of activated complement components.

(1) Note. This subclass provides for immunoglobulin preparations that are suitable for intravenous use, since they have been treated to remove aggregated, fragmented, or denatured immunoglobulins, or they have been treated to remove plasma proteins, such as proteolytic enzymes, that co-purify with immunoglobulins and which can denature immunoglobulins, or they have been otherwise treated to reduce the number of activated complement components. Immunoglobulin preparations that are free from aggregated, denatured, fragmented, or polymerized immunoglobulins are less apt to be antigenic or "anticomplementary" in vivo (i.e., are less apt to bind complement, thus setting off the undesired consequences of the complement cascade).